The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy
Abstract
CD8+ CTL play important roles against malignancy in both active and passive immunotherapy. Nonetheless, the success of antitumor CTL responses may be improved by additional therapeutic modalities. Radiotherapy, which has a long-standing use in treating neoplastic disease, has been found to induce unique biologic alterations in cancer cells affecting Fas gene expression, which, consequently, may influence the overall lytic efficiency of CTL. Here, in a mouse adenocarcinoma cell model, we examined whether exposure of these tumor cells to sublethal doses of irradiation 1) enhances Fas expression, leading to more efficient CTL killing via Fas-dependent mechanisms in vitro; and 2) improves antitumor activity in vivo by adoptive transfer of these Ag-specific CTL. Treatment of carcinoembryonic Ag-expressing MC38 adenocarcinoma cells with irradiation (20 Gy) in vitro enhanced Fas expression at molecular, phenotypic, and functional levels. Furthermore, irradiation sensitized these targets to Ag-specific CTL killing via the Fas/Fas ligand pathway. We examined the effect of localized irradiation of s.c. growing tumors on the efficiency of CTL adoptive immunotherapy. Irradiation caused up-regulation of Fas by these tumor cells in situ, based on immunohistochemistry. Moreover, localized irradiation of the tumor significantly potentiated tumor rejection by these carcinoembryonic Ag-specific CTL. Overall, these results showed for the first time that 1) regulation of the Fas pathway in tumor cells by irradiation plays an important role in their sensitization to Ag-specific CTL; and 2) a combination regimen of tumor-targeted irradiation and CTL promotes more effective antitumor responses in vivo, which may have implications for the combination of immunotherapy and radiation therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current Protocols in Immunology
(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,566
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Lymphocyte-Mediated Cytotoxicity
Russell, J. H., & Ley, T. J. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100201.131730 · Cited by 1,122
MATURE T LYMPHOCYTE APOPTOSIS—Immune Regulation in a Dynamic and Unpredictable Antigenic Environment
Lenardo, M., Chan, F. K.-M., Hornung, F., McFarland, H., Siegel, R., Wang, J., & Zheng, L. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.221 · Cited by 943
A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
Rosenberg, S. A. (1999) · Immunity · doi:10.1016/s1074-7613(00)80028-x · Cited by 566
The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity
Siegel, R. M., Ka-Ming Chan, F., Chun, H. J., & Lenardo, M. J. (2000) · Nature Immunology · doi:10.1038/82712 · Cited by 431
Workshop R: Tumor Immunology, Abstract R1 bis R30
(2001) · Immunobiology · doi:10.1016/s0171-2985(04)70018-2 · Cited by 312
MHC antigens and tumor escape from immune surveillance
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)83005-0 · Cited by 305
A triad of costimulatory molecules synergize to amplify T-cell activation.
Hodge, J. W., Sabzevari, H., Yafal, A. G., Gritz, L. R., Lorenz, M. G., & Schlom, J. (1999) · PubMed · Cited by 297
Self-citationRole of Fas-mediated cell death in the regulation of immune responses
van Parijs, L., & Abbas, A. K. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80125-7 · Cited by 238
Immune Modulation by Ionizing Radiation and its Implications for Cancer Immunotherapy
Friedman, E. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023394089 · Cited by 201
Kass, E. S., Schlom, J., Thompson, J., Guadagni, F., Graziano, P., & Greiner, J. W. (1999) · PubMed · Cited by 176
GAUGLER, C. S. (1997) · International Journal of Radiation Biology · doi:10.1080/095530097143428 · Cited by 163
Nagata, S. (1996) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-0274-0_12 · Cited by 156
Robbins, P. F., Kantor, J. A., Salgaller, M. L., Hand, P. H., Fernsten, P. D., & Schlom, J. (1991) · PubMed · Cited by 150
Esquivel-Guadarrama, F. R., Yewdell, J. W., & Bennink, J. R. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.175.1.163 · Cited by 137
Progress in the development of immunotherapy for the treatment of patients with cancer
Rosenberg, S. A. (2001) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2001.00911.x · Cited by 136
Immunologic mechanisms of antitumor activity
Foss, F. M. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.33076 · Cited by 136
Seki, N., Brooks, A. D., Carter, C. R. D., Back, T. C., Parsoneault, E. M., Smyth, M. J., Wiltrout, R. H., & Sayers, T. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3484 · Cited by 133
Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Grosenbach, D. W., Barrientos, J. C., Schlom, J., & Hodge, J. W. (2001) · PubMed · Cited by 132
Self-citationNikitina, E. Y., & Gabrilovich, D. I. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20011215)94:6<825::aid-ijc1545>3.0.co;2-5 · Cited by 131
How tumors escape immune destruction and what we can do about it
Gilboa, E. (1999) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050590 · Cited by 119
Fas and Fas ligand interactions in malignant disease.
Owen‐Schaub, L. B., Chan, H. H. L., Cusack, J. C., Roth, J. A., & Hill, L. L. (2000) · International Journal of Oncology · doi:10.3892/ijo.17.1.5 · Cited by 95
Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells.
Quarmby, S., Hunter, R. D., & Kumar, S. (2000) · PubMed · Cited by 94
Defective death receptor signaling as a cause of tumor immune escape
French, L. E., & Tschopp, J. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0405 · Cited by 93
Epigenetic changes in tumor Fas levels determine immune escape and response to therapy
Maecker, H. L., Yun, Z., Maecker, H. T., & Giaccia, A. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00095-8 · Cited by 93
Caspase Dependence of Target Cell Damage Induced by Cytotoxic Lymphocytes
Sarin, A., Haddad, E. K., & Henkart, P. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.2810 · Cited by 91
Induction and Measurement of Cytotoxic T Lymphocyte Activity
Wonderlich, J., Shearer, G. M., Livingstone, A. M., Brööks, A. G., Soloski, M. J., & Presby, M. M. (2018) · Current Protocols in Immunology · doi:10.1002/cpim.38 · Cited by 89
Mechanisms of Peripheral T Cell Tolerance
Parijs, L. V., Perez, V. L., & Abbas, A. K. (2007) · Novartis Foundation symposium · doi:10.1002/9780470515525.ch2 · Cited by 83
Cao, Z. A., Daniel, D., & Hanahan, D. (2002) · BMC Cancer · doi:10.1186/1471-2407-2-11 · Cited by 81
Kessler, B. M., Hudrisier, D., Schroeter, M., Tschopp, J., Cerottini, J., & Luescher, I. F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6939 · Cited by 72
Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses
Yee, C., & Greenberg, P. D. (2002) · Nature reviews. Cancer · doi:10.1038/nrc820 · Cited by 70
Albanese, J. M., & Dainiak, N. (2000) · Radiation Research · doi:10.1667/0033-7587(2000)153[0049:irafal]2.0.co;2 · Cited by 69
Fas‐induced apoptosis, and diseases caused by its abnormality
Nagata, S. (1996) · Genes to Cells · doi:10.1046/j.1365-2443.1996.d01-214.x · Cited by 66
T-Cell Adoptive Therapy of Tumors: Mechanisms of Improved Therapeutic Performance
Peng, L., Cohen, P. A., Kjærgaard, J., Plautz, G. E., Finke, J. H., Koski, G. K., Czerniecki, B. J., & Shu, S. (2001) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v21.i1-3.150 · Cited by 51
Ionizing radiation as a response‐enhancing agent for CD95‐mediated apoptosis
Sheard, M. A. (2001) · International Journal of Cancer · doi:10.1002/ijc.1020 · Cited by 44
Do CTL kill target cells by inducing apoptosis?
Henkart, P. A., Williams, M. S., Zacharchuk, C., & Sarin, A. (1997) · Seminars in Immunology · doi:10.1006/smim.1997.0063 · Cited by 40
Fas function and tumor progression: Use it and lose it
Owen‐Schaub, L. B. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00099-5 · Cited by 40
Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer
Schlom, J., Kantor, J. A., Abrams, S. I., Tsang, K. Y., Panicali, D., & Hamilton, J. M. (1996) · Breast Cancer Research and Treatment · doi:10.1007/bf01803781 · Cited by 39
Self-citationMyeloma and the newly diagnosed patient: A focus on treatment and management
Rajkumar, S. V., Kyle, R. A., & Gertz, M. A. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70054-7 · Cited by 37
Specific Immunotherapy Using a Recombinant Vaccinia Virus Expressing Human Carcinoembryonic Antigen
Kantor, J. A., Abrams, S. I., Irvine, K. R., Snoy, P. J., Kaufman, H. L., & Schlom, J. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb44034.x · Cited by 28
Self-citationIonizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope
Ciernik, I. F., Romero, P. J., Berzofsky, J. A., & Carbone, D. P. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00226-6 · Cited by 28
Immunotherapy against antigenic tumors: a game with a lot of players
Pérez‐Díez, A., & Marincola, F. M. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8419-5 · Cited by 16
Hareyama, M., Imai, K., Ban, T., Koshiba, H., Kubo, K., Shidou, M., Oouchi, A., & Morita, K. (1988) · PubMed · Cited by 8
Cited by
Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Self-citationKwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966
Metadata
- Authors
- Chakraborty, M., Abrams, S. I., Camphausen, K., Liu, K., Scott, T., Coleman, C. N., & Hodge, J. W.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-06
- Volume
- 170
- Issue
- 12
- Pages
- 6338-6347
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1536264784
- Cited by
- 467
- References
- 44
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.